Clinical use of tacrolimus (TAC), an essential immunosuppressant following transplantation,
is complexified by its high pharmacokinetic (PK) variability. The gut microbiota gains …

Tacrolimus dosing to establish therapeutic levels in recipients of organ transplants is a
challenging task because of much interpatient and intrapatient variability in drug absorption …

Background. Tacrolimus trough variability is an important risk factor for kidney allograft
outcomes. Recent evidence suggests that the gut microbiota is associated with tacrolimus …

Background Following solid organ transplantation, tacrolimus (TAC) is an essential drug in
the immunosuppressive strategy. Its use constitutes a challenge due to its narrow …

Introduction Effective tacrolimus (TAC) dosing is hampered by complex pharmacokinetics
and significant patient variability. The gut microbiome, a key mediator of endotoxemia …

Introduction In kidney transplantation, tacrolimus (TAC) is at the cornerstone of current
immunosuppressive strategies. Though because of its narrow therapeutic index, it is critical …

The human microbiome is associated with human health and disease. Exogenous
compounds, including pharmaceutical products, are also known to be affected by the …

Both immunosuppressants and antibiotics (ABX) are indispensable for transplant patients.
However, the former increases the risk of new-onset diabetes, whereas the latter impacts …

Post-transplant diabetes mellitus (PTDM) increases the risk of graft failure and death in liver
transplant (LT) recipients. Experimental studies have indicated that enteric dysbiosis …

Inter-and intrapatient variability of tacrolimus exposure is a vital prognostic risk factor for the
clinical outcome of liver transplantation. New factors or biomarkers characterizing tacrolimus …